Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas† (English)
- New search for: Ramanathan, R. K.
- New search for: Goldstein, D.
- New search for: Korn, R. L.
- New search for: Arena, F.
- New search for: Moore, M.
- New search for: Siena, S.
- New search for: Teixeira, L.
- New search for: Tabernero, J.
- New search for: Van Laethem, J. L.
- New search for: Liu, H.
- New search for: Ramanathan, R. K.
- New search for: Goldstein, D.
- New search for: Korn, R. L.
- New search for: Arena, F.
- New search for: Moore, M.
- New search for: Siena, S.
- New search for: Teixeira, L.
- New search for: Tabernero, J.
- New search for: Van Laethem, J. L.
- New search for: Liu, H.
In:
ANNALS OF ONCOLOGY
;
27
, 4
;
648-653
;
2016
-
ISSN:
- Article (Journal) / Print
-
Title:Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas†
-
Contributors:Ramanathan, R. K. ( author ) / Goldstein, D. ( author ) / Korn, R. L. ( author ) / Arena, F. ( author ) / Moore, M. ( author ) / Siena, S. ( author ) / Teixeira, L. ( author ) / Tabernero, J. ( author ) / Van Laethem, J. L. ( author ) / Liu, H. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 27, 4 ; 648-653
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2016-01-01
-
Size:6 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27, Issue 4
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 553
-
Medication to reduce breast cancer risk: why is uptake low?Butow, P. / Phillips, K. A. et al. | 2016
- 555
-
HER2 imaging in the ZEPHIR studyClark, A. S. / DeMichele, A. / Mankoff, D. et al. | 2016
- 557
-
Another surprising role for exosomes? Improving next-generation sequencing-based cancer diagnostics in liquid biopsiesSzallasi, Z. et al. | 2016
- 559
-
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperChampiat, S. / Lambotte, O. / Barreau, E. / Belkhir, R. / Berdelou, A. / Carbonnel, F. / Cauquil, C. / Chanson, P. / Collins, M. / Durrbach, A. et al. | 2016
- 575
-
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisSmith, S. G. / Sestak, I. / Forster, A. / Partridge, A. / Side, L. / Wolf, M. S. / Horne, R. / Wardle, J. / Cuzick, J. et al. | 2016
- 590
-
Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancerSchild, S. E. / Vokes, E. E. et al. | 2016
- 599
-
IDH mutations in cancer and progress toward development of targeted therapeuticsDang, L. / Yen, K. / Attar, E. C. et al. | 2016
- 608
-
Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysisTruong, J. / Lee, E. K. / Trudeau, M. E. / Chan, K. K. et al. | 2016
- 619
-
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trialGebhart, G. / Lamberts, L. E. / Wimana, Z. / Garcia, C. / Emonts, P. / Ameye, L. / Stroobants, S. / Huizing, M. / Aftimos, P. / Tol, J. et al. | 2016
- 625
-
Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsiesPetrillo, M. / Zannoni, G. F. / Beltrame, L. / Martinelli, E. / DiFeo, A. / Paracchini, L. / Craparotta, I. / Mannarino, L. / Vizzielli, G. / Scambia, G. et al. | 2016
- 635
-
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomesSan Lucas, F. A. / Allenson, K. / Bernard, V. / Castillo, J. / Kim, D. U. / Ellis, K. / Ehli, E. A. / Davies, G. E. / Petersen, J. L. / Li, D. et al. | 2016
- 642
-
Clinical correlation of extensive-stage small-cell lung cancer genomicsDowlati, A. / Lipka, M. B. / McColl, K. / Dabir, S. / Behtaj, M. / Kresak, A. / Miron, A. / Yang, M. / Sharma, N. / Fu, P. et al. | 2016
- 648
-
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas†Ramanathan, R. K. / Goldstein, D. / Korn, R. L. / Arena, F. / Moore, M. / Siena, S. / Teixeira, L. / Tabernero, J. / Van Laethem, J. L. / Liu, H. et al. | 2016
- 654
-
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerChiorean, E. G. / Von Hoff, D. D. / Reni, M. / Arena, F. P. / Infante, J. R. / Bathini, V. G. / Wood, T. E. / Mainwaring, P. N. / Muldoon, R. T. / Clingan, P. R. et al. | 2016
- 660
-
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junctionKlevebro, F. / Alexandersson von Döbeln, G. / Wang, N. / Johnsen, G. / Jacobsen, A. B. / Friesland, S. / Hatlevoll, I. / Glenjen, N. I. / Lind, P. / Tsai, J. A. et al. | 2016
- 668
-
Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial†Fazio, N. / Biffi, R. / Maibach, R. / Hayoz, S. / Thierstein, S. / Brauchli, P. / Bernhard, J. / Stupp, R. / Andreoni, B. / Renne, G. et al. | 2016
- 673
-
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†Al-Batran, S. E. / Van Cutsem, E. / Oh, S. C. / Bodoky, G. / Shimada, Y. / Hironaka, S. / Sugimoto, N. / Lipatov, O. N. / Kim, T. Y. / Cunningham, D. et al. | 2016
- 680
-
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinomaCiuleanu, T. / Bazin, I. / Lungulescu, D. / Miron, L. / Bondarenko, I. / Deptala, A. / Rodriguez-Torres, M. / Giantonio, B. / Fox, N. L. / Wissel, P. et al. | 2016
- 687
-
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trialGrenader, T. / Waddell, T. / Peckitt, C. / Oates, J. / Starling, N. / Cunningham, D. / Bridgewater, J. et al. | 2016
- 693
-
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer†Carter, C. A. / Rajan, A. / Keen, C. / Szabo, E. / Khozin, S. / Thomas, A. / Brzezniak, C. / Guha, U. / Doyle, L. A. / Steinberg, S. M. et al. | 2016
- 699
-
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsFizazi, K. / Flaig, T. W. / Stöckle, M. / Scher, H. I. / de Bono, J. S. / Rathkopf, D. E. / Ryan, C. J. / Kheoh, T. / Li, J. / Todd, M. B. et al. | 2016
- 706
-
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO studyPérez-Valderrama, B. / Arranz Arija, J. A. / Rodríguez Sánchez, A. / Pinto Marín, A. / Borrega García, P. / Castellano Gaunas, D. E. / Rubio Romero, G. / Maximiano Alonso, C. / Villa Guzmán, J. C. / Puertas Álvarez, J. L. et al. | 2016
- 712
-
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomasKim, S. J. / Shin, D. Y. / Kim, J. S. / Yoon, D. H. / Lee, W. S. / Lee, H. / Do, Y. R. / Kang, H. J. / Eom, H. S. / Ko, Y. H. et al. | 2016
- 719
-
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)†Cottereau, A. S. / Becker, S. / Broussais, F. / Casasnovas, O. / Kanoun, S. / Roques, M. / Charrier, N. / Bertrand, S. / Delarue, R. / Bonnet, C. et al. | 2016
- 725
-
European cancer mortality predictions for the year 2016 with focus on leukaemiasMalvezzi, M. / Carioli, G. / Bertuccio, P. / Rosso, T. / Boffetta, P. / Levi, F. / La Vecchia, C. / Negri, E. et al. | 2016
- 732
-
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabFerrucci, P. F. / Ascierto, P. A. / Pigozzo, J. / Del Vecchio, M. / Maio, M. / Antonini Cappellini, G. C. / Guidoboni, M. / Queirolo, P. / Savoia, P. / Mandalà, M. et al. | 2016
- 738
-
Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterationsBousquet, M. / Noirot, C. / Accadbled, F. / Sales de Gauzy, J. / Castex, M. P. / Brousset, P. / Gomez-Brouchet, A. et al. | 2016
- 745
-
The GILDA trial finds no survival benefit from intensified screening after primary resection of colorectal cancer: the PulMiCC trial tests the survival benefit of pulmonary metastasectomy for detected asymptomatic lung metastasesTreasure, T. / Macbeth, F. et al. | 2016
- 746
-
Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumorsvan Adrichem, R. C. / Kamp, K. / Vandamme, T. / Peeters, M. / Feelders, R. A. / de Herder, W. W. et al. | 2016
- 747
-
Number needed to treat for pricing costly anticancer drugs: the example of regorafenib in metastatic colorectal cancerGraziano, F. / Rulli, E. / Biagioli, E. / Catalano, V. et al. | 2016
- 748
-
Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity†Takeda, M. / Sakai, K. / Okamoto, K. / Hayashi, H. / Tanaka, K. / Shimizu, T. / Nishio, K. / Nakagawa, K. et al. | 2016
- 750
-
Reply to the letter to the editor ‘Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy’ by Tannock et al.Parker, C. / Gillessen, S. / Heidenreich, A. / Horwich, A. et al. | 2016
- 751
-
Survival in young adults diagnosed with follicular lymphomaCalvo, V. / Provencio, M. / Gómez Codina, J. / Rodríguez Abreu, D. / Rueda, A. et al. | 2016
- 752
-
Drug–drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacistsGelderblom, H. / Köhne, C. H. / Launay-Vacher, V. / van Leeuwen, R. W. et al. | 2016
- 753
-
Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogramGroot Koerkamp, B. / Wiggers, J. K. / Gonen, M. / Doussot, A. / Allen, P. J. / Besselink, M. G. / Blumgart, L. H. / Busch, O. R. / D'Angelica, M. I. / DeMatteo, R. P. et al. | 2016